Highlight
BIA-ALCL is a heterogeneous T cell lymphoma arising in women with textured breast implants with variable gene expression profiles.
The cell of origin is a memory CD4+ or CD8+ T cell identified by unique TCR rearrangement and gene expression patterns.
The tumor immune microenvironment (TIME) is complex, featuring distinct myeloid populations and elevated immunosuppressive cytokines including IL-10, IL-13, and TNF.
BIA-ALCL induces T cell exhaustion and immune evasion, revealing potential novel immunotherapeutic targets for advanced disease.
